EpiCept Announces Positive Results for AZIXA In Brain Cancer
EpiCept Corporation (EPCT) announced that its drug AZIXA showed positive results in a phase 1 clinical trial in brain cancer patients. The study was conducted by EpiCept's partner Myriad Genetics (MYGN).
Myriad was able to achieve the drug's maximum tolerable dosage in patients with cancer that has metastasized to the brain. Results also showed a reduction in tumor size, suggesting that AZIXA exhibits some activity. Myriad plans to bring the drug to phase 2 trials soon after it finalizes the therapeutic dosage.
EpiCept gained more than 20% to end trading at $2.04 a share, while Myriad gained 1.90% to $24.18.
_
EpiCept Corporation (EPCT) announced that its drug AZIXA showed positive results in a phase 1 clinical trial in brain cancer patients. The study was conducted by EpiCept's partner Myriad Genetics (MYGN).
Myriad was able to achieve the drug's maximum tolerable dosage in patients with cancer that has metastasized to the brain. Results also showed a reduction in tumor size, suggesting that AZIXA exhibits some activity. Myriad plans to bring the drug to phase 2 trials soon after it finalizes the therapeutic dosage.
EpiCept gained more than 20% to end trading at $2.04 a share, while Myriad gained 1.90% to $24.18.
_
posted by Nico at
8:50 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home